BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bogen JP, Carrara SC, Fiebig D, Grzeschik J, Hock B, Kolmar H. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture. Front Immunol 2021;12:669496. [PMID: 34040611 DOI: 10.3389/fimmu.2021.669496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lampros EA, Kremer PG, Aguilar Díaz de León JS, Roberts ET, Rodriguez Benavente MC, Amster IJ, Barb AW. The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites. Curr Res Immunol 2022;3:128-35. [PMID: 35712026 DOI: 10.1016/j.crimmu.2022.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Harwardt J, Bogen JP, Carrara SC, Ulitzka M, Grzeschik J, Hock B, Kolmar H. A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization. Front Immunol 2022;13:888838. [DOI: 10.3389/fimmu.2022.888838] [Reference Citation Analysis]
3 Natale V, Stadlmayr G, Benedetti F, Stadlbauer K, Rüker F, Wozniak-Knopp G. Trispecific antibodies produced from mAb2 pairs by controlled Fab-arm exchange. Biol Chem 2022. [PMID: 35089662 DOI: 10.1515/hsz-2021-0376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lian G, Mak TS, Yu X, Lan HY. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. Int J Mol Sci 2021;23:164. [PMID: 35008589 DOI: 10.3390/ijms23010164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Barrière S, El-Ghazzi N, Garcia M, Guièze R. [Bispecific antibodies in onco-hematology: Applications and perspectives]. Bull Cancer 2021;108:S195-204. [PMID: 34920803 DOI: 10.1016/j.bulcan.2021.10.002] [Reference Citation Analysis]
6 Surowka M, Schaefer W, Klein C. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs 2021;13:1967714. [PMID: 34491877 DOI: 10.1080/19420862.2021.1967714] [Cited by in F6Publishing: 7] [Reference Citation Analysis]